期刊文献+

干扰素治疗骨髓增殖性肿瘤诱发癫痫2例分析 被引量:1

下载PDF
导出
摘要 骨髓增殖性肿瘤(myeloproliferative neoplasm,MPN)是一组起源于造血干/祖细胞的恶性克隆性疾病,是以一系或多系髓系细胞增殖为主要特征的造血系统肿瘤,表现为外周血或骨髓出现过多的成熟或幼稚细胞,并对细胞因子敏感性增加。包括真性红细胞增多症、原发性血小板增多症、特发性骨髓纤维化、慢性粒细胞白血病等。
出处 《实用肿瘤杂志》 CAS 2015年第6期570-572,共3页 Journal of Practical Oncology
基金 河北省科学技术研究与发展计划项目(08966107D)
  • 相关文献

参考文献7

  • 1Park MS, Kim BR, Kang S, et al. The antihypertension drug doxazosin suppresses JAK/STATs phosphorylation and enhances the effects of IFN-cJ/-induced apoptosis [ J ]. Genes Cancer,2014,5 ( 11-12 ) :470 - 479.
  • 2成志勇,李士辉,杨琳,黄月华,潘崚.干扰素α对JAK2V617阳性的骨髓增殖性疾病的影响[J].实用肿瘤杂志,2008,23(4):318-321. 被引量:11
  • 3Rizzi M, Messina G, Castiglione M, et al. Intrathecal interferon-induced seizure [ J ]. Acta Neurochir ( Wien), 2013,155 ( 11 ) :2199 - 2200.
  • 4James C, Ugo V, Couedic JPL, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera [ J ]. Nature, 2005,434 ( 7037 ) : 1144 - 1148.
  • 5Geyer HL, Mesa RA. Therapy for myeloproliferative neoplasms : when, which agent and how [ J ] ? Blood, 2014, 124 ( 24 ) : 3529 - 2537.
  • 6Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia : 2015 update on diagnosis, risk- stratification and management [ J ]. Am J Hematol, 2015, 90(2) :162 - 173.
  • 7Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis [ J ]. Clin Cancer Res ,2012,18 ( 11 ) :3008 - 3014.

二级参考文献10

  • 1Kralovics R,Passamonti F,Buser AS. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [J]. N Engl J Med, 2005, 352 (17) :1779 - 1790.
  • 2Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J]. Cancer Cell,2005, 7(4) :387-397.
  • 3Goerttler PS, Steimle C, Marz E. et al. The Jak 2V617F mutation, PRV- 1 overexpression, and EEC formation define a similar cohort of MPD patients [J]. Blood,2005,106(8):2862-2864.
  • 4Shih LY,Lee CT,Ou YC. Prediction of clinical course in patients with idiopathic erythrocytosis by endogenous erythroid colony assay but not by serum erythropoietin levels [J]. Exp Hematol, 1997,25(4):288-292.
  • 5Lacout C, Pisani DF, Tulliez M. et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis [J]. Blood, 2006,108 (5):1652-1660.
  • 6Temerinac S, Klippel S,Strunck E,et al. Cloning of PRV-1 mRNA,a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera[J]. Blood,2000,95(8):2569-2576.
  • 7Vannucchi AM, Guglielmelli P, Antonioli E, et al. Inconsistencies in the association between the JAK2 (V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases [J]. Br J Haematol, 2006,132 (5) : 652 - 654.
  • 8Massaro P ,Foa P ,Pomati M ,et al. Polycythemia vera treated with recombinant interferon-alpha 2α: evidence of a selective effect on the malignant clone [J]. AmJHematol,1997,56(2):126-128.
  • 9Steimle C, Lehmann U, Temerinac S. Biomarker analysis in polycythemia vera under interferon-alpha treatment., clonality, EEC, PRV-1, and JAK 2 V617F [J]. Ann Hematol, 2007,86 (4) :239 -244.
  • 10白洁,邵宗鸿,刘鸿,施均,何广胜,曹燕然,崔振珠,孙娟,田征,贾海蓉,钱林生,杨天楹,杨崇礼.真性红细胞增多症患者内源性红系集落检测及其临床意义[J].中华血液学杂志,2003,24(11):561-564. 被引量:4

共引文献10

同被引文献6

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部